Navigation Links
Medivir: R&D Day
Date:11/18/2010

Medivir: R&D Day -- LONDON, November 18, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Surveys, Polls and Research, Clinical Trials & Medical Discoveries Click to view news release full screen  

Medivir: R&D Day

 

LONDON, November 18, 2010 /PRNewswire/ --

- Today, 12:30 GMT, 13:30 CET, London

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, will today host an R&D day for sell-side analysts, investors and the media at the offices of M:Communications, 1 Ropemaker Street, 34th Floor, London EC2Y. Registration for the event will commence at 12:30 (GMT)/13:30 (CET)/7.30 (EST).

Medivir's CEO, Ron Long, and CFO, Rein Piir, will chair the event together with other key members of Medivir's management team including Eva Arlander, VP Medivir Pharma, Paul Wallace, VP Business Development, and Bertil Samuelsson, CSO. Together they will discuss the clinical development of Medivir's key pipeline asset TMC435, a once daily hepatitis C protease inhibitor in phase 2b development, which is jointly developed by Medivir and Tibotec Pharmaceuticals, and present an update on the product and R&D pipeline.

In order to access the event remotely, a live audio webcast will be streamed from the R&D session. To access the webcast please visit the Company's website http://www.medivir.se.

In a separate press release issued today Medivir announced positive phase 2b TMC435 data from the ASPIRE (C206) study. These results will be discussed during the R&D session via a conference call at 15:00 (GMT)/ 16:00 (CET)/10:00 (EST).

To participate in the conference call at 15:00 (GMT) which will discuss the phase 2b TMC435 ASPIRE (C206) data announced today please dial: UK: +44- (0)20-7906-8535, Sweden Access Number: +46(0)85-063-9549 or US Access Number: +1-703-865-2821. A seven day replay of the conference call can be accessed via: UK: +44(0)20-3364-5943, Sweden: +46(0)20-089-6353, US: +1- 866-286-6997, please quote the passcode 281259#.

About Medivir

Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese(TM)/Xerclear(R). Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese(TM)/Xerclear(R) is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear(R) in Sweden and Finland.

For more information about Medivir, please visit the Company's website: http://www.medivir.se.

For more information about Medivir, please contact: Medivir (http://www.medivir.se) Rein Piir, CFO & VP Investor Relations Mobile: +46-708-537-292 M:Communications Europe: Mary-Jane Elliott / Emma Thompson / Amber Bielecka Medivir@mcomgroup.com +44(0)20-7920-2330 USA: Jason Marshall +1-212-897-5497
'/>"/>

SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. R&D and Demand Draw Medical Biotech Companies and Device Makers to Germany
2. Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025
3. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
4. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
5. RIKEN Center for Genomics Medicine Chooses Genedata Expressionist for High Throughput Proteomics R&D
6. US Nanotechnology Instrument Manufacturer Proves the Success of R&D Stimulus
7. Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
8. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
9. Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery
10. UMass Boston Opens Venture Development Center to Expand R&D Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a Research ... U.S. Small Business Administration. The Tibbetts Award honors the Small Business Innovation ... and are considered the best of the best from the thousands of firms ...
(Date:1/13/2017)... -- Research and Markets has announced the addition of ... to 2021" report to their offering. ... The biosimilars market is expected to ... 2016, at a CAGR of 26.3%. The global ... and application. Factors such as rising incidence of various diseases, increasing ...
(Date:1/13/2017)... Island, NY (PRWEB) , ... January 13, 2017 ... ... teamed up with several companies to offer its customers three new solutions for ... probe would come in handy if a customer has an oddly-shaped sample that ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):